UroGen Pharma Ltd. Ordinary Shares
URGNUroGen Pharma Ltd. is a biotechnology company focused on developing innovative solutions for urological and uro-oncological conditions. The company's portfolio includes targeted therapies designed to improve treatment outcomes for patients with conditions such as bladder cancer and other genitourinary diseases. UroGen aims to leverage advanced drug delivery technologies to enhance safety and efficacy in urological treatments.
Company News
UroGen Pharma granted restricted stock units to 14 new employees to support commercialization of Jelmyto and ZUSDURI, with up to 32,500 ordinary shares issuable upon vesting over three years.
The U.S. Food and Drug Administration (FDA) questioned the efficacy and utility of UroGen Pharma's experimental bladder cancer therapy UGN-102, causing the company's stock price to fall significantly.
Urogen Pharma (URGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
The company released positive top-line results for two studies for a bladder cancer treatment.
